Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Two Sigma Investments LP

Two Sigma Investments LP lowered its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 70.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 24,987 shares of the specialty pharmaceutical company's stock after selling 59,580 shares during the period. Two Sigma Investments LP's holdings in Supernus Pharmaceuticals were worth $904,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. raised its stake in shares of Supernus Pharmaceuticals by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company's stock worth $222,411,000 after purchasing an additional 22,852 shares during the last quarter. Geode Capital Management LLC increased its holdings in Supernus Pharmaceuticals by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company's stock worth $54,633,000 after buying an additional 28,517 shares during the period. American Century Companies Inc. raised its position in Supernus Pharmaceuticals by 9.2% during the 4th quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company's stock worth $41,248,000 after buying an additional 95,777 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Supernus Pharmaceuticals by 5.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company's stock worth $27,242,000 after buying an additional 40,968 shares during the last quarter. Finally, Northern Trust Corp raised its position in Supernus Pharmaceuticals by 18.3% during the 4th quarter. Northern Trust Corp now owns 717,161 shares of the specialty pharmaceutical company's stock worth $25,933,000 after buying an additional 110,867 shares during the last quarter.

Supernus Pharmaceuticals Trading Up 2.5%

SUPN opened at $33.15 on Friday. Supernus Pharmaceuticals, Inc. has a 12-month low of $25.53 and a 12-month high of $40.28. The firm has a market capitalization of $1.86 billion, a PE ratio of 30.98 and a beta of 0.71. The firm has a 50 day moving average of $31.95 and a two-hundred day moving average of $34.47.

Analyst Upgrades and Downgrades

SUPN has been the subject of a number of recent research reports. Wall Street Zen raised shares of Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, May 16th. Cantor Fitzgerald reissued a "neutral" rating and set a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.